AstraZeneca breaks ground on $475 million drug plant in Wuxi
UK-based pharma major AstraZeneca (LSE: AZN) has started construction on a new manufacturing site for small molecule drugs in Wuxi, a city in East China's Jiangsu province, underscoring its deepening investment in the country.
The groundbreaking took place on May 8, marking a significant step in AstraZeneca's long-term commitment to its second-largest market. The $475 million facility will use advanced continuous direct compression methods and sustainable packaging lines, with intelligent automation and digital systems woven throughout the site.
The new project follows the company’s decision earlier this year to abandon plans for a £450 million ($567 million) vaccine manufacturing site in Liverpool, UK. That decision came as a political setback to the British government, which is eager to boost private-sector investment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze